BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Boehringer Ingelheim
Cerilliant
AstraZeneca
Cantor Fitzgerald
McKesson
Baxter
Citi
Dow
Chinese Patent Office

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020719

« Back to Dashboard

NDA 020719 describes PRELAY, which is a drug marketed by Sankyo and is included in one NDA. There are two patents protecting this drug. Additional details are available on the PRELAY profile page.

The generic ingredient in PRELAY is troglitazone. Additional details are available on the troglitazone profile page.
Summary for 020719
Tradename:PRELAY
Applicant:Sankyo
Ingredient:troglitazone
Patents:2
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength200MG
Approval Date:Jan 29, 1997TE:RLD:No
Patent:➤ SubscribePatent Expiration:Nov 13, 2017Product Flag?Substance Flag?Delist Request?
Patented Use:USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
Patent:➤ SubscribePatent Expiration:Nov 13, 2017Product Flag?Substance Flag?Delist Request?
Patented Use:USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength400MG
Approval Date:Jan 29, 1997TE:RLD:No
Patent:➤ SubscribePatent Expiration:Nov 13, 2017Product Flag?Substance Flag?Delist Request?
Patented Use:USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES

Expired US Patents for NDA 020719

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sankyo PRELAY troglitazone TABLET;ORAL 020719-002 Jan 29, 1997 ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-001 Jan 29, 1997 ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-003 Aug 4, 1997 ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-001 Jan 29, 1997 ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-003 Aug 4, 1997 ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-003 Aug 4, 1997 ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-001 Jan 29, 1997 ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-002 Jan 29, 1997 ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-003 Aug 4, 1997 ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-002 Jan 29, 1997 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Merck
Mallinckrodt
Deloitte
US Department of Justice
Moodys
AstraZeneca
Chinese Patent Office
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot